How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about daratumumab

    Marketing authorisation indication

    2.1 Daratumumab (Darzalex, Janssen-Cilag) is 'indicated in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis'.

    Dosage in the marketing authorisation

    2.2 The dosage schedule is available in the summary of product characteristics.

    Price

    2.3 The list price of daratumumab is £4,320 for a 1,800 mg per 15 ml vial (excluding VAT; BNF online accessed December 2021). Costs may vary in different settings because of negotiated procurement discounts. The company has a commercial arrangement. This makes daratumumab available to the NHS with a discount, and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.